87 related articles for article (PubMed ID: 38487720)
1. Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study.
Bouroumeau A; Perdikis-Prati S; Lang N
Front Oncol; 2024; 14():1308492. PubMed ID: 38487720
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
4. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR
Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
6. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.
Perdikis-Prati S; Sheikh S; Bouroumeau A; Lang N
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371815
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
Jain N; Senapati J; Thakral B; Ferrajoli A; Thompson P; Burger J; Basu S; Kadia T; Daver N; Borthakur G; Konopleva M; Pemmaraju N; Parry E; Wu CJ; Khoury J; Bueso-Ramos C; Garg N; Wang X; Lopez W; Ayala A; O'Brien S; Kantarjian H; Keating M; Allison J; Sharma P; Wierda W
Blood Adv; 2023 May; 7(10):1958-1966. PubMed ID: 36287248
[TBL] [Abstract][Full Text] [Related]
9. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of durvalumab with R-CHOP or R
Nowakowski GS; Willenbacher W; Greil R; Larsen TS; Patel K; Jäger U; Manges RF; Trümper L; Everaus H; Kalakonda N; Brown P; Jørgensen JM; Cunningham D; Dell'Aringa J; Fox B; Rubio ND; Kilavuz N; Casadebaig ML; Manzke O; Munoz J
Int J Hematol; 2022 Feb; 115(2):222-232. PubMed ID: 34797531
[TBL] [Abstract][Full Text] [Related]
11. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas.
Hübschmann D; Kleinheinz K; Wagener R; Bernhart SH; López C; Toprak UH; Sungalee S; Ishaque N; Kretzmer H; Kreuz M; Waszak SM; Paramasivam N; Ammerpohl O; Aukema SM; Beekman R; Bergmann AK; Bieg M; Binder H; Borkhardt A; Borst C; Brors B; Bruns P; Carrillo de Santa Pau E; Claviez A; Doose G; Haake A; Karsch D; Haas S; Hansmann ML; Hoell JI; Hovestadt V; Huang B; Hummel M; Jäger-Schmidt C; Kerssemakers JNA; Korbel JO; Kube D; Lawerenz C; Lenze D; Martens JHA; Ott G; Radlwimmer B; Reisinger E; Richter J; Rico D; Rosenstiel P; Rosenwald A; Schillhabel M; Stilgenbauer S; Stadler PF; Martín-Subero JI; Szczepanowski M; Warsow G; Weniger MA; Zapatka M; Valencia A; Stunnenberg HG; Lichter P; Möller P; Loeffler M; Eils R; Klapper W; Hoffmann S; Trümper L; ; ; ; Küppers R; Schlesner M; Siebert R
Leukemia; 2021 Jul; 35(7):2002-2016. PubMed ID: 33953289
[TBL] [Abstract][Full Text] [Related]
12. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
Jeong AR; Ball ED; Goodman AM
Clin Med Insights Oncol; 2020; 14():1179554920976366. PubMed ID: 33447123
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
